Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Short Interest Update

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the recipient of a significant decline in short interest in June. As of June 15th, there was short interest totaling 4,540 shares, a decline of 90.0% from the May 31st total of 45,360 shares. Based on an average daily volume of 92,782 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.1% of the company’s stock are sold short.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Sonoma Pharmaceuticals stock. McKinley Carter Wealth Services Inc. bought a new position in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 11,193 shares of the company’s stock, valued at approximately $41,000. McKinley Carter Wealth Services Inc. owned 0.66% of Sonoma Pharmaceuticals as of its most recent SEC filing. 1.95% of the stock is currently owned by institutional investors.

Sonoma Pharmaceuticals Trading Down 1.8%

Shares of NASDAQ:SNOA opened at $1.12 on Friday. The stock has a market capitalization of $5.36 million, a PE ratio of -0.59 and a beta of 1.29. Sonoma Pharmaceuticals has a 1 year low of $0.85 and a 1 year high of $6.92. The firm has a fifty day moving average price of $1.26 and a 200 day moving average price of $2.38.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last posted its earnings results on Tuesday, June 16th. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.09). Sonoma Pharmaceuticals had a negative net margin of 16.26% and a negative return on equity of 43.95%. The company had revenue of $5.56 million for the quarter, compared to the consensus estimate of $5.57 million.

Analysts Set New Price Targets

Separately, Weiss Ratings downgraded Sonoma Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, April 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.